nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Epirubicin—bone cancer	0.206	1	CrCtD
Doxorubicin—Anthracyclines—Epirubicin—bone cancer	0.167	0.657	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—bone cancer	0.0873	0.343	CiPCiCtD
Doxorubicin—Valrubicin—Epirubicin—bone cancer	0.0438	0.333	CrCrCtD
Doxorubicin—Idarubicin—Epirubicin—bone cancer	0.0438	0.333	CrCrCtD
Doxorubicin—Daunorubicin—Epirubicin—bone cancer	0.0438	0.333	CrCrCtD
Doxorubicin—thyroid cancer—bone cancer	0.0331	0.186	CtDrD
Doxorubicin—CYP3A4—bone cancer	0.0296	1	CbGaD
Doxorubicin—breast cancer—bone cancer	0.0269	0.152	CtDrD
Doxorubicin—prostate cancer—bone cancer	0.025	0.141	CtDrD
Doxorubicin—AURKA—Epirubicin—bone cancer	0.0243	0.176	CbGbCtD
Doxorubicin—YWHAG—Epirubicin—bone cancer	0.0243	0.176	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—bone cancer	0.0243	0.176	CbGbCtD
Doxorubicin—muscle cancer—bone cancer	0.0217	0.122	CtDrD
Doxorubicin—kidney cancer—bone cancer	0.0181	0.102	CtDrD
Doxorubicin—peripheral nervous system neoplasm—bone cancer	0.018	0.101	CtDrD
Doxorubicin—lung cancer—bone cancer	0.0175	0.0985	CtDrD
Doxorubicin—sarcoma—bone cancer	0.0173	0.0973	CtDrD
Doxorubicin—NQO1—Carboplatin—bone cancer	0.0103	0.0744	CbGbCtD
Doxorubicin—NQO1—Cisplatin—bone cancer	0.00881	0.0635	CbGbCtD
Doxorubicin—ABCC6—Cisplatin—bone cancer	0.00737	0.0532	CbGbCtD
Doxorubicin—XDH—Carboplatin—bone cancer	0.00539	0.0389	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—bone cancer	0.00495	0.0357	CbGbCtD
Doxorubicin—XDH—Cisplatin—bone cancer	0.0046	0.0332	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—bone cancer	0.00365	0.0264	CbGbCtD
Doxorubicin—ABCC3—Cisplatin—bone cancer	0.00354	0.0255	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—bone cancer	0.00274	0.0198	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—bone cancer	0.0023	0.0166	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—bone cancer	0.00188	0.0136	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—bone cancer	0.0017	0.0123	CbGbCtD
Doxorubicin—ABCC2—Cisplatin—bone cancer	0.00161	0.0116	CbGbCtD
Doxorubicin—ABCG2—Cisplatin—bone cancer	0.00145	0.0105	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—bone cancer	0.00141	0.0102	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—bone cancer	0.00104	0.00753	CbGbCtD
Doxorubicin—CYP2B6—Cisplatin—bone cancer	0.00102	0.00738	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—bone cancer	0.000944	0.00681	CbGbCtD
Doxorubicin—ABCB1—Cisplatin—bone cancer	0.000524	0.00378	CbGbCtD
Doxorubicin—NOS3—hindlimb—bone cancer	0.000362	0.0735	CbGeAlD
Doxorubicin—ABCB1—Methotrexate—bone cancer	0.00034	0.00246	CbGbCtD
Doxorubicin—NOS3—appendage—bone cancer	0.00031	0.063	CbGeAlD
Doxorubicin—NOS2—tendon—bone cancer	0.000221	0.0448	CbGeAlD
Doxorubicin—SLC22A16—bone marrow—bone cancer	0.000177	0.036	CbGeAlD
Doxorubicin—CBR3—Idarubicin—Epirubicin—bone cancer	0.000145	0.289	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—bone cancer	0.000145	0.289	CbGdCrCtD
Doxorubicin—NDUFS7—connective tissue—bone cancer	0.00014	0.0284	CbGeAlD
Doxorubicin—CBR3—tendon—bone cancer	0.000137	0.0278	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—bone cancer	0.000116	0.0235	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—bone cancer	0.000114	0.0232	CbGeAlD
Doxorubicin—ABCC6—connective tissue—bone cancer	0.000106	0.0215	CbGeAlD
Doxorubicin—AKR1A1—tendon—bone cancer	0.000106	0.0215	CbGeAlD
Doxorubicin—AKR1A1—bone marrow—bone cancer	0.000102	0.0208	CbGeAlD
Doxorubicin—AKR1A1—spinal cord—bone cancer	0.000102	0.0207	CbGeAlD
Doxorubicin—YWHAG—connective tissue—bone cancer	9.97e-05	0.0202	CbGeAlD
Doxorubicin—NDUFS7—tendon—bone cancer	9.6e-05	0.0195	CbGeAlD
Doxorubicin—NDUFS7—bone marrow—bone cancer	9.3e-05	0.0189	CbGeAlD
Doxorubicin—NDUFS7—spinal cord—bone cancer	9.26e-05	0.0188	CbGeAlD
Doxorubicin—AURKA—tendon—bone cancer	8.93e-05	0.0181	CbGeAlD
Doxorubicin—NOS3—connective tissue—bone cancer	8.86e-05	0.018	CbGeAlD
Doxorubicin—AURKA—bone marrow—bone cancer	8.65e-05	0.0176	CbGeAlD
Doxorubicin—NOS1—tendon—bone cancer	8.01e-05	0.0163	CbGeAlD
Doxorubicin—NDUFS2—tendon—bone cancer	7.96e-05	0.0162	CbGeAlD
Doxorubicin—NDUFS3—tendon—bone cancer	7.86e-05	0.016	CbGeAlD
Doxorubicin—NOS1—spinal cord—bone cancer	7.72e-05	0.0157	CbGeAlD
Doxorubicin—NDUFS2—bone marrow—bone cancer	7.71e-05	0.0157	CbGeAlD
Doxorubicin—NDUFS2—spinal cord—bone cancer	7.68e-05	0.0156	CbGeAlD
Doxorubicin—AURKA—Idarubicin—Epirubicin—bone cancer	7.64e-05	0.152	CbGdCrCtD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—bone cancer	7.64e-05	0.152	CbGdCrCtD
Doxorubicin—NDUFS3—bone marrow—bone cancer	7.61e-05	0.0155	CbGeAlD
Doxorubicin—NDUFS3—spinal cord—bone cancer	7.58e-05	0.0154	CbGeAlD
Doxorubicin—DHCR7—bone marrow—bone cancer	7.24e-05	0.0147	CbGeAlD
Doxorubicin—DHCR7—spinal cord—bone cancer	7.2e-05	0.0146	CbGeAlD
Doxorubicin—YWHAG—tendon—bone cancer	6.85e-05	0.0139	CbGeAlD
Doxorubicin—NQO1—connective tissue—bone cancer	6.74e-05	0.0137	CbGeAlD
Doxorubicin—YWHAG—bone marrow—bone cancer	6.64e-05	0.0135	CbGeAlD
Doxorubicin—YWHAG—spinal cord—bone cancer	6.61e-05	0.0134	CbGeAlD
Doxorubicin—RALBP1—tendon—bone cancer	6.19e-05	0.0126	CbGeAlD
Doxorubicin—NOS3—tendon—bone cancer	6.09e-05	0.0124	CbGeAlD
Doxorubicin—RALBP1—bone marrow—bone cancer	6e-05	0.0122	CbGeAlD
Doxorubicin—RALBP1—spinal cord—bone cancer	5.97e-05	0.0121	CbGeAlD
Doxorubicin—CBR1—tendon—bone cancer	5.78e-05	0.0117	CbGeAlD
Doxorubicin—AKR1C3—tendon—bone cancer	5.71e-05	0.0116	CbGeAlD
Doxorubicin—CBR1—bone marrow—bone cancer	5.6e-05	0.0114	CbGeAlD
Doxorubicin—CBR1—spinal cord—bone cancer	5.57e-05	0.0113	CbGeAlD
Doxorubicin—AKR1C3—bone marrow—bone cancer	5.53e-05	0.0112	CbGeAlD
Doxorubicin—AKR1C3—spinal cord—bone cancer	5.5e-05	0.0112	CbGeAlD
Doxorubicin—POR—tendon—bone cancer	5.21e-05	0.0106	CbGeAlD
Doxorubicin—POR—bone marrow—bone cancer	5.05e-05	0.0102	CbGeAlD
Doxorubicin—POR—spinal cord—bone cancer	5.03e-05	0.0102	CbGeAlD
Doxorubicin—TOP2A—tendon—bone cancer	4.86e-05	0.00986	CbGeAlD
Doxorubicin—CYP1B1—connective tissue—bone cancer	4.73e-05	0.0096	CbGeAlD
Doxorubicin—TOP2A—bone marrow—bone cancer	4.7e-05	0.00955	CbGeAlD
Doxorubicin—NQO1—tendon—bone cancer	4.63e-05	0.0094	CbGeAlD
Doxorubicin—NQO1—spinal cord—bone cancer	4.46e-05	0.00907	CbGeAlD
Doxorubicin—ABCC10—tendon—bone cancer	4.13e-05	0.0084	CbGeAlD
Doxorubicin—ABCC10—bone marrow—bone cancer	4e-05	0.00813	CbGeAlD
Doxorubicin—ABCC10—spinal cord—bone cancer	3.99e-05	0.0081	CbGeAlD
Doxorubicin—ABCC2—tendon—bone cancer	3.32e-05	0.00674	CbGeAlD
Doxorubicin—CYP1B1—tendon—bone cancer	3.25e-05	0.0066	CbGeAlD
Doxorubicin—ABCC1—tendon—bone cancer	2.92e-05	0.00594	CbGeAlD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—bone cancer	2.92e-05	0.0582	CbGdCrCtD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—bone cancer	2.92e-05	0.0582	CbGdCrCtD
Doxorubicin—ABCG2—bone marrow—bone cancer	2.35e-05	0.00476	CbGeAlD
Doxorubicin—ABCG2—spinal cord—bone cancer	2.33e-05	0.00474	CbGeAlD
Doxorubicin—Ataxia—Epirubicin—bone cancer	1.22e-05	0.000333	CcSEcCtD
Doxorubicin—Nervous system disorder—Cisplatin—bone cancer	1.21e-05	0.000333	CcSEcCtD
Doxorubicin—Thrombocytopenia—Cisplatin—bone cancer	1.21e-05	0.000332	CcSEcCtD
Doxorubicin—Blood creatinine increased—Epirubicin—bone cancer	1.21e-05	0.000332	CcSEcCtD
Doxorubicin—Tachycardia—Cisplatin—bone cancer	1.21e-05	0.000331	CcSEcCtD
Doxorubicin—Dehydration—Epirubicin—bone cancer	1.2e-05	0.00033	CcSEcCtD
Doxorubicin—Skin disorder—Cisplatin—bone cancer	1.2e-05	0.00033	CcSEcCtD
Doxorubicin—Hyperhidrosis—Cisplatin—bone cancer	1.2e-05	0.000328	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—bone cancer	1.2e-05	0.000327	CcSEcCtD
Doxorubicin—Liver function test abnormal—Epirubicin—bone cancer	1.2e-05	0.000327	CcSEcCtD
Doxorubicin—Dry skin—Epirubicin—bone cancer	1.19e-05	0.000325	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—bone cancer	1.18e-05	0.000324	CcSEcCtD
Doxorubicin—Abdominal pain upper—Epirubicin—bone cancer	1.18e-05	0.000324	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Epirubicin—bone cancer	1.18e-05	0.000324	CcSEcCtD
Doxorubicin—Anorexia—Cisplatin—bone cancer	1.18e-05	0.000323	CcSEcCtD
Doxorubicin—Hypokalaemia—Epirubicin—bone cancer	1.18e-05	0.000323	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—bone cancer	1.17e-05	0.000321	CcSEcCtD
Doxorubicin—Breast disorder—Epirubicin—bone cancer	1.17e-05	0.00032	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Epirubicin—bone cancer	1.17e-05	0.000319	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Epirubicin—bone cancer	1.17e-05	0.000319	CcSEcCtD
Doxorubicin—Hypotension—Cisplatin—bone cancer	1.16e-05	0.000317	CcSEcCtD
Doxorubicin—Nasopharyngitis—Epirubicin—bone cancer	1.16e-05	0.000317	CcSEcCtD
Doxorubicin—ABCB1—bone marrow—bone cancer	1.16e-05	0.00235	CbGeAlD
Doxorubicin—ABCB1—spinal cord—bone cancer	1.15e-05	0.00234	CbGeAlD
Doxorubicin—Gastritis—Epirubicin—bone cancer	1.15e-05	0.000314	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Epirubicin—bone cancer	1.14e-05	0.000313	CcSEcCtD
Doxorubicin—Muscular weakness—Epirubicin—bone cancer	1.14e-05	0.000313	CcSEcCtD
Doxorubicin—Pancytopenia—Methotrexate—bone cancer	1.14e-05	0.000311	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Cisplatin—bone cancer	1.13e-05	0.000309	CcSEcCtD
Doxorubicin—Abdominal distension—Epirubicin—bone cancer	1.13e-05	0.000309	CcSEcCtD
Doxorubicin—Asthma—Epirubicin—bone cancer	1.12e-05	0.000306	CcSEcCtD
Doxorubicin—Influenza—Epirubicin—bone cancer	1.12e-05	0.000306	CcSEcCtD
Doxorubicin—Dysphagia—Epirubicin—bone cancer	1.12e-05	0.000306	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—bone cancer	1.12e-05	0.000306	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—bone cancer	1.12e-05	0.000306	CcSEcCtD
Doxorubicin—Paraesthesia—Cisplatin—bone cancer	1.11e-05	0.000305	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Methotrexate—bone cancer	1.11e-05	0.000304	CcSEcCtD
Doxorubicin—Eosinophilia—Epirubicin—bone cancer	1.11e-05	0.000303	CcSEcCtD
Doxorubicin—Dyspnoea—Cisplatin—bone cancer	1.1e-05	0.000303	CcSEcCtD
Doxorubicin—Pancreatitis—Epirubicin—bone cancer	1.1e-05	0.0003	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Methotrexate—bone cancer	1.09e-05	0.000299	CcSEcCtD
Doxorubicin—Angina pectoris—Epirubicin—bone cancer	1.09e-05	0.000299	CcSEcCtD
Doxorubicin—Decreased appetite—Cisplatin—bone cancer	1.08e-05	0.000295	CcSEcCtD
Doxorubicin—Bronchitis—Epirubicin—bone cancer	1.08e-05	0.000295	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—bone cancer	1.07e-05	0.000294	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Cisplatin—bone cancer	1.07e-05	0.000293	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—bone cancer	1.07e-05	0.000292	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—bone cancer	1.07e-05	0.000292	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—bone cancer	1.07e-05	0.000292	CcSEcCtD
Doxorubicin—Pancytopenia—Epirubicin—bone cancer	1.06e-05	0.000291	CcSEcCtD
Doxorubicin—Pain—Cisplatin—bone cancer	1.06e-05	0.00029	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—bone cancer	1.06e-05	0.000289	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—bone cancer	1.05e-05	0.000287	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—bone cancer	1.05e-05	0.000287	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—bone cancer	1.05e-05	0.000287	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—bone cancer	1.04e-05	0.000285	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—bone cancer	1.04e-05	0.000285	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—bone cancer	1.04e-05	0.000284	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—bone cancer	1.03e-05	0.000283	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—bone cancer	1.02e-05	0.00028	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—bone cancer	1.02e-05	0.00028	CcSEcCtD
Doxorubicin—Feeling abnormal—Cisplatin—bone cancer	1.02e-05	0.00028	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—bone cancer	1.02e-05	0.000279	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—bone cancer	1.02e-05	0.000278	CcSEcCtD
Doxorubicin—Weight decreased—Epirubicin—bone cancer	1.01e-05	0.000277	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—bone cancer	1.01e-05	0.000276	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—bone cancer	1.01e-05	0.000276	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—bone cancer	1.01e-05	0.000275	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—bone cancer	1e-05	0.000275	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—bone cancer	9.98e-06	0.000273	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—bone cancer	9.98e-06	0.000273	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—bone cancer	9.98e-06	0.000273	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—bone cancer	9.95e-06	0.000272	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—bone cancer	9.89e-06	0.000271	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—bone cancer	9.81e-06	0.000269	CcSEcCtD
Doxorubicin—Body temperature increased—Cisplatin—bone cancer	9.79e-06	0.000268	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—bone cancer	9.78e-06	0.000268	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—bone cancer	9.72e-06	0.000266	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—bone cancer	9.72e-06	0.000266	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—bone cancer	9.7e-06	0.000266	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—bone cancer	9.7e-06	0.000266	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—bone cancer	9.62e-06	0.000263	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—bone cancer	9.57e-06	0.000262	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—bone cancer	9.57e-06	0.000262	CcSEcCtD
Doxorubicin—Sweating—Epirubicin—bone cancer	9.56e-06	0.000262	CcSEcCtD
Doxorubicin—Haematuria—Epirubicin—bone cancer	9.51e-06	0.000261	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—bone cancer	9.5e-06	0.00026	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—bone cancer	9.45e-06	0.000259	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Epirubicin—bone cancer	9.43e-06	0.000258	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—bone cancer	9.41e-06	0.000258	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—bone cancer	9.38e-06	0.000257	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—bone cancer	9.36e-06	0.000256	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—bone cancer	9.31e-06	0.000255	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—bone cancer	9.22e-06	0.000253	CcSEcCtD
Doxorubicin—Hypersensitivity—Cisplatin—bone cancer	9.13e-06	0.00025	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—bone cancer	9.12e-06	0.00025	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—bone cancer	9.05e-06	0.000248	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—bone cancer	9e-06	0.000247	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—bone cancer	8.98e-06	0.000246	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—bone cancer	8.95e-06	0.000245	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—bone cancer	8.95e-06	0.000245	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—bone cancer	8.94e-06	0.000245	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—bone cancer	8.92e-06	0.000244	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—bone cancer	8.91e-06	0.000244	CcSEcCtD
Doxorubicin—Asthenia—Cisplatin—bone cancer	8.89e-06	0.000243	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—bone cancer	8.89e-06	0.000243	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—bone cancer	8.88e-06	0.000243	CcSEcCtD
Doxorubicin—Urinary tract disorder—Epirubicin—bone cancer	8.84e-06	0.000242	CcSEcCtD
Doxorubicin—Oedema peripheral—Epirubicin—bone cancer	8.82e-06	0.000242	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—bone cancer	8.8e-06	0.000241	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—bone cancer	8.78e-06	0.00024	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—bone cancer	8.68e-06	0.000238	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—bone cancer	8.64e-06	0.000237	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—bone cancer	8.63e-06	0.000236	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—bone cancer	8.62e-06	0.000236	CcSEcCtD
Doxorubicin—Chills—Methotrexate—bone cancer	8.59e-06	0.000235	CcSEcCtD
Doxorubicin—Diarrhoea—Cisplatin—bone cancer	8.48e-06	0.000232	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—bone cancer	8.47e-06	0.000232	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—bone cancer	8.46e-06	0.000232	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—bone cancer	8.38e-06	0.00023	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—bone cancer	8.37e-06	0.000229	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—bone cancer	8.35e-06	0.000229	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—bone cancer	8.33e-06	0.000228	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—bone cancer	8.33e-06	0.000228	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—bone cancer	8.31e-06	0.000228	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—bone cancer	8.31e-06	0.000228	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—bone cancer	8.16e-06	0.000223	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—bone cancer	8.12e-06	0.000223	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—bone cancer	8.09e-06	0.000222	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—bone cancer	8.07e-06	0.000221	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—bone cancer	8.06e-06	0.000221	CcSEcCtD
Doxorubicin—Chills—Epirubicin—bone cancer	8.03e-06	0.00022	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—bone cancer	8e-06	0.000219	CcSEcCtD
Doxorubicin—Alopecia—Epirubicin—bone cancer	7.91e-06	0.000217	CcSEcCtD
Doxorubicin—Vomiting—Cisplatin—bone cancer	7.88e-06	0.000216	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—bone cancer	7.85e-06	0.000215	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—bone cancer	7.85e-06	0.000215	CcSEcCtD
Doxorubicin—Rash—Cisplatin—bone cancer	7.81e-06	0.000214	CcSEcCtD
Doxorubicin—Dermatitis—Cisplatin—bone cancer	7.8e-06	0.000214	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—bone cancer	7.8e-06	0.000214	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—bone cancer	7.8e-06	0.000214	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—bone cancer	7.73e-06	0.000212	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—bone cancer	7.7e-06	0.000211	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—bone cancer	7.68e-06	0.00021	CcSEcCtD
Doxorubicin—Tension—Epirubicin—bone cancer	7.65e-06	0.00021	CcSEcCtD
Doxorubicin—Dysgeusia—Epirubicin—bone cancer	7.63e-06	0.000209	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—bone cancer	7.57e-06	0.000207	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—bone cancer	7.54e-06	0.000207	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—bone cancer	7.51e-06	0.000206	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—bone cancer	7.49e-06	0.000205	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—bone cancer	7.48e-06	0.000205	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—bone cancer	7.46e-06	0.000204	CcSEcCtD
Doxorubicin—Nausea—Cisplatin—bone cancer	7.36e-06	0.000202	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—bone cancer	7.35e-06	0.000201	CcSEcCtD
Doxorubicin—Cough—Methotrexate—bone cancer	7.27e-06	0.000199	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—bone cancer	7.23e-06	0.000198	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—bone cancer	7.22e-06	0.000198	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—bone cancer	7.2e-06	0.000197	CcSEcCtD
Doxorubicin—Agitation—Epirubicin—bone cancer	7.16e-06	0.000196	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—bone cancer	7.09e-06	0.000194	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—bone cancer	7.09e-06	0.000194	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—bone cancer	7.09e-06	0.000194	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.04e-06	0.000193	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—bone cancer	7.03e-06	0.000193	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—bone cancer	7.01e-06	0.000192	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—bone cancer	7e-06	0.000192	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—bone cancer	6.99e-06	0.000192	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—bone cancer	6.98e-06	0.000191	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—bone cancer	6.89e-06	0.000189	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—bone cancer	6.85e-06	0.000188	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—bone cancer	6.85e-06	0.000188	CcSEcCtD
Doxorubicin—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	6.81e-06	0.000334	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—GSTP1—bone cancer	6.81e-06	0.000334	CbGpPWpGaD
Doxorubicin—Cough—Epirubicin—bone cancer	6.8e-06	0.000186	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—bone cancer	6.8e-06	0.000186	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—NT5C3A—bone cancer	6.78e-06	0.000333	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—CYP3A4—bone cancer	6.77e-06	0.000332	CbGpPWpGaD
Doxorubicin—Convulsion—Epirubicin—bone cancer	6.75e-06	0.000185	CcSEcCtD
Doxorubicin—Infection—Methotrexate—bone cancer	6.75e-06	0.000185	CcSEcCtD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.73e-06	0.00033	CbGpPWpGaD
Doxorubicin—Hypertension—Epirubicin—bone cancer	6.73e-06	0.000184	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—bone cancer	6.67e-06	0.000183	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—bone cancer	6.66e-06	0.000182	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	6.64e-06	0.000326	CbGpPWpGaD
Doxorubicin—Arthralgia—Epirubicin—bone cancer	6.64e-06	0.000182	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—bone cancer	6.64e-06	0.000182	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—bone cancer	6.64e-06	0.000182	CcSEcCtD
Doxorubicin—Anxiety—Epirubicin—bone cancer	6.61e-06	0.000181	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—bone cancer	6.6e-06	0.000181	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.59e-06	0.000181	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—bone cancer	6.57e-06	0.00018	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—bone cancer	6.56e-06	0.00018	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.53e-06	0.000321	CbGpPWpGaD
Doxorubicin—Dry mouth—Epirubicin—bone cancer	6.49e-06	0.000178	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—bone cancer	6.48e-06	0.000178	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—SMO—bone cancer	6.47e-06	0.000318	CbGpPWpGaD
Doxorubicin—Confusional state—Epirubicin—bone cancer	6.41e-06	0.000176	CcSEcCtD
Doxorubicin—ABCC1—Metabolism—NDUFA12—bone cancer	6.41e-06	0.000315	CbGpPWpGaD
Doxorubicin—Anaphylactic shock—Epirubicin—bone cancer	6.36e-06	0.000174	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—bone cancer	6.36e-06	0.000174	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—bone cancer	6.35e-06	0.000174	CcSEcCtD
Doxorubicin—YWHAG—Apoptosis—TP53—bone cancer	6.34e-06	0.000311	CbGpPWpGaD
Doxorubicin—Infection—Epirubicin—bone cancer	6.32e-06	0.000173	CcSEcCtD
Doxorubicin—CBR1—Metabolism—CYP3A4—bone cancer	6.31e-06	0.00031	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.3e-06	0.000309	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.28e-06	0.000308	CbGpPWpGaD
Doxorubicin—Shock—Epirubicin—bone cancer	6.26e-06	0.000171	CcSEcCtD
Doxorubicin—AURKA—Cell Cycle—RB1—bone cancer	6.26e-06	0.000307	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—PLAU—bone cancer	6.26e-06	0.000307	CbGpPWpGaD
Doxorubicin—Nervous system disorder—Epirubicin—bone cancer	6.24e-06	0.000171	CcSEcCtD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.23e-06	0.000306	CbGpPWpGaD
Doxorubicin—Thrombocytopenia—Epirubicin—bone cancer	6.23e-06	0.000171	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—bone cancer	6.21e-06	0.00017	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism—NDUFA12—bone cancer	6.2e-06	0.000305	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—bone cancer	6.19e-06	0.00017	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—bone cancer	6.18e-06	0.000169	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—bone cancer	6.15e-06	0.000168	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—bone cancer	6.15e-06	0.000168	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—bone cancer	6.1e-06	0.000167	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CDK4—bone cancer	6.1e-06	0.000299	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CHEK2—bone cancer	6.07e-06	0.000298	CbGpPWpGaD
Doxorubicin—Anorexia—Epirubicin—bone cancer	6.06e-06	0.000166	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—bone cancer	6.06e-06	0.000166	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—bone cancer	6.04e-06	0.000166	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—bone cancer	5.98e-06	0.000164	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—bone cancer	5.94e-06	0.000163	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—GNA11—bone cancer	5.92e-06	0.00029	CbGpPWpGaD
Doxorubicin—Decreased appetite—Methotrexate—bone cancer	5.91e-06	0.000162	CcSEcCtD
Doxorubicin—CYP2B6—Biological oxidations—GSTP1—bone cancer	5.9e-06	0.00029	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ENO2—bone cancer	5.88e-06	0.000288	CbGpPWpGaD
Doxorubicin—Gastrointestinal disorder—Methotrexate—bone cancer	5.87e-06	0.000161	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—GRM4—bone cancer	5.87e-06	0.000288	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—RGS1—bone cancer	5.87e-06	0.000288	CbGpPWpGaD
Doxorubicin—Fatigue—Methotrexate—bone cancer	5.86e-06	0.000161	CcSEcCtD
Doxorubicin—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	5.82e-06	0.000286	CbGpPWpGaD
Doxorubicin—Pain—Methotrexate—bone cancer	5.81e-06	0.000159	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—bone cancer	5.8e-06	0.000159	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—GSTP1—bone cancer	5.79e-06	0.000284	CbGpPWpGaD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—EGFR—bone cancer	5.79e-06	0.000284	CbGpPWpGaD
Doxorubicin—Insomnia—Epirubicin—bone cancer	5.75e-06	0.000158	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—bone cancer	5.71e-06	0.000156	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.68e-06	0.000279	CbGpPWpGaD
Doxorubicin—Dyspnoea—Epirubicin—bone cancer	5.67e-06	0.000155	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—bone cancer	5.66e-06	0.000155	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	5.65e-06	0.000277	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NDUFA12—bone cancer	5.64e-06	0.000277	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Methotrexate—bone cancer	5.6e-06	0.000153	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—bone cancer	5.6e-06	0.000153	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—bone cancer	5.56e-06	0.000152	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—bone cancer	5.53e-06	0.000152	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—ATF1—bone cancer	5.5e-06	0.00027	CbGpPWpGaD
Doxorubicin—Gastrointestinal disorder—Epirubicin—bone cancer	5.49e-06	0.00015	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—bone cancer	5.49e-06	0.00015	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—CDK4—bone cancer	5.46e-06	0.000268	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—JUN—bone cancer	5.45e-06	0.000268	CbGpPWpGaD
Doxorubicin—NOS2—Disease—DHFR—bone cancer	5.45e-06	0.000268	CbGpPWpGaD
Doxorubicin—Constipation—Epirubicin—bone cancer	5.44e-06	0.000149	CcSEcCtD
Doxorubicin—Pain—Epirubicin—bone cancer	5.44e-06	0.000149	CcSEcCtD
Doxorubicin—Urticaria—Methotrexate—bone cancer	5.4e-06	0.000148	CcSEcCtD
Doxorubicin—AKR1C3—Disease—ENO2—bone cancer	5.4e-06	0.000265	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—GSTP1—bone cancer	5.4e-06	0.000265	CbGpPWpGaD
Doxorubicin—Body temperature increased—Methotrexate—bone cancer	5.37e-06	0.000147	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—bone cancer	5.37e-06	0.000147	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—IL3—bone cancer	5.36e-06	0.000263	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—MDM2—bone cancer	5.34e-06	0.000262	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—NT5C3A—bone cancer	5.32e-06	0.000261	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—RB1—bone cancer	5.31e-06	0.00026	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—TP53—bone cancer	5.27e-06	0.000258	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Epirubicin—bone cancer	5.24e-06	0.000144	CcSEcCtD
Doxorubicin—NOS1—Disease—TGFBR2—bone cancer	5.24e-06	0.000257	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Epirubicin—bone cancer	5.2e-06	0.000143	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle—BRCA2—bone cancer	5.14e-06	0.000253	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.14e-06	0.000252	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—NT5C3A—bone cancer	5.14e-06	0.000252	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—GRM1—bone cancer	5.09e-06	0.00025	CbGpPWpGaD
Doxorubicin—Urticaria—Epirubicin—bone cancer	5.05e-06	0.000138	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—bone cancer	5.03e-06	0.000138	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—bone cancer	5.03e-06	0.000138	CcSEcCtD
Doxorubicin—AKR1C3—Disease—DHFR—bone cancer	5.01e-06	0.000246	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Methotrexate—bone cancer	5.01e-06	0.000137	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—RGS1—bone cancer	4.96e-06	0.000243	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GRM4—bone cancer	4.96e-06	0.000243	CbGpPWpGaD
Doxorubicin—Asthenia—Methotrexate—bone cancer	4.88e-06	0.000134	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—PLAU—bone cancer	4.86e-06	0.000239	CbGpPWpGaD
Doxorubicin—Pruritus—Methotrexate—bone cancer	4.81e-06	0.000132	CcSEcCtD
Doxorubicin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	4.8e-06	0.000235	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—RB1—bone cancer	4.74e-06	0.000233	CbGpPWpGaD
Doxorubicin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	4.73e-06	0.000232	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Epirubicin—bone cancer	4.69e-06	0.000128	CcSEcCtD
Doxorubicin—NQO1—Metabolism—ENO2—bone cancer	4.69e-06	0.00023	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	4.68e-06	0.00023	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—NT5C3A—bone cancer	4.68e-06	0.00023	CbGpPWpGaD
Doxorubicin—Diarrhoea—Methotrexate—bone cancer	4.65e-06	0.000127	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	4.62e-06	0.000227	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TGFBR2—bone cancer	4.59e-06	0.000225	CbGpPWpGaD
Doxorubicin—Asthenia—Epirubicin—bone cancer	4.56e-06	0.000125	CcSEcCtD
Doxorubicin—NOS3—Disease—ENO2—bone cancer	4.56e-06	0.000224	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—ENO2—bone cancer	4.52e-06	0.000222	CbGpPWpGaD
Doxorubicin—Pruritus—Epirubicin—bone cancer	4.5e-06	0.000123	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—bone cancer	4.5e-06	0.000123	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.47e-06	0.000219	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.38e-06	0.000215	CbGpPWpGaD
Doxorubicin—Diarrhoea—Epirubicin—bone cancer	4.35e-06	0.000119	CcSEcCtD
Doxorubicin—NQO1—Metabolism—DHFR—bone cancer	4.35e-06	0.000213	CbGpPWpGaD
Doxorubicin—Vomiting—Methotrexate—bone cancer	4.32e-06	0.000118	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—IGF1R—bone cancer	4.32e-06	0.000212	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GRM1—bone cancer	4.3e-06	0.000211	CbGpPWpGaD
Doxorubicin—Rash—Methotrexate—bone cancer	4.29e-06	0.000117	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—bone cancer	4.28e-06	0.000117	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	4.27e-06	0.000209	CbGpPWpGaD
Doxorubicin—Headache—Methotrexate—bone cancer	4.26e-06	0.000117	CcSEcCtD
Doxorubicin—NOS3—Disease—DHFR—bone cancer	4.23e-06	0.000208	CbGpPWpGaD
Doxorubicin—Dizziness—Epirubicin—bone cancer	4.21e-06	0.000115	CcSEcCtD
Doxorubicin—XDH—Metabolism—ENO2—bone cancer	4.2e-06	0.000206	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—DHFR—bone cancer	4.19e-06	0.000206	CbGpPWpGaD
Doxorubicin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.14e-06	0.000203	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NDUFA12—bone cancer	4.14e-06	0.000203	CbGpPWpGaD
Doxorubicin—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.1e-06	0.000201	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GNA11—bone cancer	4.06e-06	0.000199	CbGpPWpGaD
Doxorubicin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.05e-06	0.000199	CbGpPWpGaD
Doxorubicin—Vomiting—Epirubicin—bone cancer	4.05e-06	0.000111	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—MDM2—bone cancer	4.04e-06	0.000199	CbGpPWpGaD
Doxorubicin—Nausea—Methotrexate—bone cancer	4.04e-06	0.000111	CcSEcCtD
Doxorubicin—Rash—Epirubicin—bone cancer	4.01e-06	0.00011	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—bone cancer	4.01e-06	0.00011	CcSEcCtD
Doxorubicin—Headache—Epirubicin—bone cancer	3.99e-06	0.000109	CcSEcCtD
Doxorubicin—NOS2—Disease—TGFBR2—bone cancer	3.95e-06	0.000194	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GNA11—bone cancer	3.92e-06	0.000192	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	3.91e-06	0.000192	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.9e-06	0.000192	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—DHFR—bone cancer	3.9e-06	0.000191	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ENO2—bone cancer	3.82e-06	0.000188	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CDK4—bone cancer	3.82e-06	0.000187	CbGpPWpGaD
Doxorubicin—Nausea—Epirubicin—bone cancer	3.78e-06	0.000104	CcSEcCtD
Doxorubicin—NDUFS3—Metabolism—PTGS2—bone cancer	3.75e-06	0.000184	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—PTGS2—bone cancer	3.75e-06	0.000184	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.75e-06	0.000184	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	3.71e-06	0.000182	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—CYP3A4—bone cancer	3.68e-06	0.000181	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GNA11—bone cancer	3.64e-06	0.000179	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFBR2—bone cancer	3.63e-06	0.000178	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—TP53—bone cancer	3.6e-06	0.000177	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SMO—bone cancer	3.58e-06	0.000176	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KIT—bone cancer	3.57e-06	0.000175	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—CYP3A4—bone cancer	3.55e-06	0.000174	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—DHFR—bone cancer	3.54e-06	0.000174	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.54e-06	0.000174	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PTGS2—bone cancer	3.53e-06	0.000173	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—NT5C3A—bone cancer	3.43e-06	0.000168	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.37e-06	0.000165	CbGpPWpGaD
Doxorubicin—NOS1—Disease—BRAF—bone cancer	3.36e-06	0.000165	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—TP53—bone cancer	3.34e-06	0.000164	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—RB1—bone cancer	3.32e-06	0.000163	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GNA11—bone cancer	3.31e-06	0.000163	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CYP3A4—bone cancer	3.3e-06	0.000162	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—GNA11—bone cancer	3.28e-06	0.000161	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—GSTP1—bone cancer	3.15e-06	0.000155	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KIT—bone cancer	3.13e-06	0.000154	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ENO2—bone cancer	3.1e-06	0.000152	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFBR2—bone cancer	3.07e-06	0.000151	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—bone cancer	3.06e-06	0.00015	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NDUFA12—bone cancer	3.05e-06	0.00015	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ATF1—bone cancer	3.05e-06	0.00015	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—GSTP1—bone cancer	3.04e-06	0.000149	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SMO—bone cancer	3.03e-06	0.000149	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CYP3A4—bone cancer	3e-06	0.000147	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PTGS2—bone cancer	3e-06	0.000147	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL3—bone cancer	2.97e-06	0.000146	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ENO2—bone cancer	2.97e-06	0.000146	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—BRAF—bone cancer	2.94e-06	0.000144	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	2.9e-06	0.000142	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NDUFA12—bone cancer	2.88e-06	0.000141	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—DHFR—bone cancer	2.88e-06	0.000141	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—MDM2—bone cancer	2.83e-06	0.000139	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—GSTP1—bone cancer	2.83e-06	0.000139	CbGpPWpGaD
Doxorubicin—NOS1—Disease—MDM2—bone cancer	2.81e-06	0.000138	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PTGS2—bone cancer	2.8e-06	0.000137	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ENO2—bone cancer	2.78e-06	0.000136	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GNA11—bone cancer	2.77e-06	0.000136	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—DHFR—bone cancer	2.76e-06	0.000135	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PTGS2—bone cancer	2.71e-06	0.000133	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KIT—bone cancer	2.7e-06	0.000132	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GNA11—bone cancer	2.69e-06	0.000132	CbGpPWpGaD
Doxorubicin—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.68e-06	0.000132	CbGpPWpGaD
Doxorubicin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.65e-06	0.00013	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—DHFR—bone cancer	2.58e-06	0.000127	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GNA11—bone cancer	2.58e-06	0.000126	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ATF1—bone cancer	2.58e-06	0.000126	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—GSTP1—bone cancer	2.57e-06	0.000126	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFBR2—bone cancer	2.54e-06	0.000125	CbGpPWpGaD
Doxorubicin—NOS2—Disease—BRAF—bone cancer	2.53e-06	0.000124	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—NT5C3A—bone cancer	2.53e-06	0.000124	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TP53—bone cancer	2.52e-06	0.000123	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL3—bone cancer	2.51e-06	0.000123	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KIT—bone cancer	2.48e-06	0.000122	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MDM2—bone cancer	2.47e-06	0.000121	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CYP3A4—bone cancer	2.44e-06	0.00012	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.42e-06	0.000119	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IGF1R—bone cancer	2.39e-06	0.000117	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—NT5C3A—bone cancer	2.38e-06	0.000117	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CYP3A4—bone cancer	2.34e-06	0.000115	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—BRAF—bone cancer	2.33e-06	0.000114	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ENO2—bone cancer	2.33e-06	0.000114	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.32e-06	0.000114	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TP53—bone cancer	2.32e-06	0.000114	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ENO2—bone cancer	2.25e-06	0.000111	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—DHFR—bone cancer	2.16e-06	0.000106	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.15e-06	0.000106	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFBR2—bone cancer	2.15e-06	0.000105	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—JUN—bone cancer	2.14e-06	0.000105	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MDM2—bone cancer	2.12e-06	0.000104	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KIT—bone cancer	2.09e-06	0.000103	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—DHFR—bone cancer	2.09e-06	0.000103	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MMP9—bone cancer	2.08e-06	0.000102	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—GSTP1—bone cancer	2.08e-06	0.000102	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.07e-06	0.000102	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ENO2—bone cancer	2.05e-06	0.000101	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTGS2—bone cancer	2.05e-06	0.0001	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IGF1R—bone cancer	2.02e-06	9.92e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GNA11—bone cancer	2.02e-06	9.91e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—GSTP1—bone cancer	2e-06	9.81e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—BRAF—bone cancer	1.97e-06	9.66e-05	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—bone cancer	1.95e-06	9.59e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GNA11—bone cancer	1.95e-06	9.58e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MDM2—bone cancer	1.95e-06	9.58e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—EGFR—bone cancer	1.92e-06	9.44e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—DHFR—bone cancer	1.9e-06	9.33e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—bone cancer	1.88e-06	9.23e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NDUFA12—bone cancer	1.88e-06	9.23e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.87e-06	9.18e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFBR2—bone cancer	1.87e-06	9.17e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CYP3A4—bone cancer	1.83e-06	8.98e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.82e-06	8.94e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GNA11—bone cancer	1.78e-06	8.72e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CYP3A4—bone cancer	1.77e-06	8.69e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.76e-06	8.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KIT—bone cancer	1.73e-06	8.51e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EGFR—bone cancer	1.68e-06	8.27e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MDM2—bone cancer	1.65e-06	8.09e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—bone cancer	1.63e-06	8.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—BRAF—bone cancer	1.63e-06	8e-05	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—bone cancer	1.62e-06	7.97e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CYP3A4—bone cancer	1.61e-06	7.9e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—bone cancer	1.59e-06	7.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—bone cancer	1.57e-06	7.73e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—GSTP1—bone cancer	1.57e-06	7.68e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—NT5C3A—bone cancer	1.56e-06	7.65e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—GSTP1—bone cancer	1.51e-06	7.43e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ENO2—bone cancer	1.5e-06	7.37e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.47e-06	7.22e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KIT—bone cancer	1.47e-06	7.19e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—bone cancer	1.46e-06	7.19e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—bone cancer	1.45e-06	7.12e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—bone cancer	1.41e-06	6.94e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—DHFR—bone cancer	1.39e-06	6.84e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—BRAF—bone cancer	1.38e-06	6.76e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—GSTP1—bone cancer	1.38e-06	6.76e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MDM2—bone cancer	1.37e-06	6.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—bone cancer	1.33e-06	6.54e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—bone cancer	1.33e-06	6.53e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GNA11—bone cancer	1.3e-06	6.39e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KIT—bone cancer	1.28e-06	6.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.23e-06	6.06e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—BRAF—bone cancer	1.2e-06	5.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—JUN—bone cancer	1.19e-06	5.83e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP3A4—bone cancer	1.18e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—bone cancer	1.16e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MDM2—bone cancer	1.15e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—bone cancer	1.13e-06	5.53e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ENO2—bone cancer	1.11e-06	5.44e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—bone cancer	1.08e-06	5.3e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ENO2—bone cancer	1.04e-06	5.12e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—bone cancer	1.03e-06	5.08e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—DHFR—bone cancer	1.03e-06	5.04e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GSTP1—bone cancer	1.01e-06	4.96e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MDM2—bone cancer	1e-06	4.93e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—JUN—bone cancer	1e-06	4.92e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—bone cancer	9.76e-07	4.79e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—DHFR—bone cancer	9.68e-07	4.75e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—bone cancer	9.68e-07	4.75e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GNA11—bone cancer	9.6e-07	4.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—bone cancer	9.34e-07	4.58e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GNA11—bone cancer	9.05e-07	4.44e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP3A4—bone cancer	8.71e-07	4.27e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP3A4—bone cancer	8.2e-07	4.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—bone cancer	8.11e-07	3.98e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—bone cancer	7.89e-07	3.87e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—bone cancer	7.84e-07	3.85e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—bone cancer	7.84e-07	3.85e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GSTP1—bone cancer	7.45e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—bone cancer	7.14e-07	3.5e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GSTP1—bone cancer	7.02e-07	3.44e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—bone cancer	6.86e-07	3.37e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ENO2—bone cancer	6.82e-07	3.35e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—bone cancer	6.62e-07	3.25e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—DHFR—bone cancer	6.33e-07	3.11e-05	CbGpPWpGaD
Doxorubicin—Daunorubicin—CYP3A4—bone cancer	5.93e-07	1	CrCbGaD
Doxorubicin—CYP3A4—Metabolism—GNA11—bone cancer	5.92e-07	2.9e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—bone cancer	5.23e-07	2.57e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GSTP1—bone cancer	4.59e-07	2.25e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—bone cancer	3.86e-07	1.89e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—bone cancer	3.64e-07	1.78e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—bone cancer	2.38e-07	1.17e-05	CbGpPWpGaD
